Please enable JS

Product pipelines

Therapeutic antibodies:

Monocarboxylate transporter 4 (MCT4) is highly expressed in malignant tumour cells due to reprogrammed metabolism termed Warburg effect. Though having been long proved as a valid therapeutic target in many cancer types, MCT4-targeting therapeutics is still lacking due to its cell membrane protein nature and the unrevealed 3D protein structure. At Pharmaplanter Technologies, we are pursuing therapeutic MCT4 antibody development using the unique MPS Discovery Engine at Integral Molecular (http://www.integralmolecular. com). The project is currently under active phage display library generation and the screening experiment will be launched in a very short period of time.

Therapeutic nanoparticles:

MCT4-targeting RNAi medicine development is another active project at Pharmaplanter Technologies. The unique polymer nanoparticle technology platform applied is from our collaborator Dr. Shi’s laboratory (https://connects.catalyst.har on/43651). Different MCT4-RNAi nano-medicines have been developed and have shown promising efficacies in vitro in varied prostate cancer cell lines. Preclinical evaluation is under way in a panel of prostate cancer PDX models.

Therapeutical small molecules:

Dysregulation of mRNA translation is revealed as a frequent and unique feature of neoplasia. Numerous research studies have demonstrated eIF4E is an important nodal point in mRNA translation pathway and a proven therapeutic target. At Pharmaplanter Technologies, we have recently launched a therapeutic development program to develop small molecule inhibitors specifically targeting eIF4E, based on new binding pocket sites identified in its 3D structure.

Mitochondria therapeutics for age-related degeneration diseases:

Mutations in mitochondrial DNA (mtDNA), in nuclear-encoded mitochondrial component genes, and age-dependent mitochondrial damage, have all been connected with numerous human health disorders, such as encephalomyopathy, myoclonic epilepsy, Alzheimer's, Parkinson's and Huntington's disease. Unravelling the molecular aetiology of mitochondrial dysfunction opens new therapeutic prospects for diseases thus far lacking effective treatments. At Pharmaplanter Technologies, we also develop new technology for in vivo delivery of healthy mitochondria and modulation of mitochondrial dynamics at the level of biogenesis, fission, fusion, movement and mitophagy.


At Pharmaplanter Technologies, we have successfully developed a series of nutraceutical health products covering the eye, joints, liver, brain and cellular health. Detailed information about these products can be found at: